DROXIDOPA NEW

$6.00 1000kg

$7.00 100kg

$8.00 1kg

Min. Order1kg
Purity99%
Cas No23651-95-8
Supply Abilityg-kg-tons, free sample is available
Update time2024-04-23

Henan Fengda Chemical Co., Ltd

1YR

China

Chemical Properties

Product Name	DROXIDOPA
CAS No	23651-95-8
EC-No
Min. Order	1kg
Purity	99%
Supply Ability	g-kg-tons, free sample is available
Release date	2024/04/23

1. Product information

Name	DROXIDOPA
Synonym	More Synonyms

Description	Droxidopa(L-DOPS, SM5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); capable of crossing the protective blood–brain barrierIC50 value: Target: The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow [1]. L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline [2].
Related Catalog	Signaling Pathways >> Others >> Others Natural Products >> Phenylpropanoids Research Areas >> Neurological Disease
References	[1]. Coll M, et al. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. Hepatology. 2012 Nov;56(5):1849-60. [2]. Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res. 2008 Mar;18 Suppl 1:25-9.

Description

Droxidopa(L-DOPS, SM5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); capable of crossing the protective blood–brain barrierIC50 value: Target: The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow [1]. L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline [2].

Related Catalog

Signaling Pathways >> Others >> Others

Natural Products >> Phenylpropanoids

Research Areas >> Neurological Disease

References

[1]. Coll M, et al. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. Hepatology. 2012 Nov;56(5):1849-60.

[2]. Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res. 2008 Mar;18 Suppl 1:25-9.

Density	1.608g/cm3
Boiling Point	549.8±50.0 °C at 760 mmHg
Melting Point	232-235° (dec); mp 229-232° (dec) (Ohashi)
Molecular Formula	C9H11NO5
Molecular Weight	213.187
Flash Point	286.3±30.1 °C
Exact Mass	213.063721
PSA	124.01000
LogP	-0.95
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.692
Storage condition	2-8C